Work

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study by Number of Prior Lines Oftherapy and Prior Therapies

Year: 2020

Type: article

Source: Hematology Transfusion and Cell Therapy

DOI: 10.1016/j.htct.2020.10.425

Authors: H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli

Institutions: The University of Melbourne, St Vincent's Hospital Melbourne, Emory University, Winship Cancer Institute, Nizhny Novgorod Regional Clinical Hospital named after Semashko, University of Alberta, Cross Cancer Institute, Hôpital Claude Huriez, Alfred Health, Monash University, University Medical Center Hamburg-Eppendorf, Instituto de Investigación Biomédica de Salamanca, Samsung Medical Center, Sungkyunkwan University, Medical University of Silesia, Japanese Red Cross Medical Center, Evangelismos Hospital, Amgen (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3096550457

FWCI: 0.135

Cites:

Cited by: 1

Related to: 10